JP2017525705A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017525705A5 JP2017525705A5 JP2017509743A JP2017509743A JP2017525705A5 JP 2017525705 A5 JP2017525705 A5 JP 2017525705A5 JP 2017509743 A JP2017509743 A JP 2017509743A JP 2017509743 A JP2017509743 A JP 2017509743A JP 2017525705 A5 JP2017525705 A5 JP 2017525705A5
- Authority
- JP
- Japan
- Prior art keywords
- dsrna agent
- nucleotides
- agent according
- administration
- dsrna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 31
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 30
- 239000003795 chemical substances by application Substances 0.000 claims 28
- 239000002773 nucleotide Substances 0.000 claims 18
- 125000003729 nucleotide group Chemical group 0.000 claims 18
- 230000000692 anti-sense effect Effects 0.000 claims 12
- 108091081021 Sense strand Proteins 0.000 claims 9
- 238000000034 method Methods 0.000 claims 7
- 238000012986 modification Methods 0.000 claims 5
- 230000004048 modification Effects 0.000 claims 5
- 101150075175 Asgr1 gene Proteins 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 238000007920 subcutaneous administration Methods 0.000 claims 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- IQFYYKKMVGJFEH-BIIVOSGPSA-N 2'-deoxythymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-BIIVOSGPSA-N 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical class CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 125000002015 acyclic group Chemical group 0.000 claims 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims 1
- 230000000368 destabilizing effect Effects 0.000 claims 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 230000001926 lymphatic effect Effects 0.000 claims 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020212527A JP7370311B2 (ja) | 2014-08-20 | 2020-12-22 | 修飾二本鎖ｒｎａ剤 |
| JP2020212528A JP7672220B2 (ja) | 2014-08-20 | 2020-12-22 | 修飾二本鎖ｒｎａ剤 |
| JP2023178574A JP7654744B2 (ja) | 2014-08-20 | 2023-10-17 | 修飾二本鎖ｒｎａ剤 |
| JP2025044214A JP2025111426A (ja) | 2014-08-20 | 2025-03-19 | 修飾二本鎖ｒｎａ剤 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462039507P | 2014-08-20 | 2014-08-20 | |
| US62/039,507 | 2014-08-20 | ||
| US201462083744P | 2014-11-24 | 2014-11-24 | |
| US62/083,744 | 2014-11-24 | ||
| US201462093919P | 2014-12-18 | 2014-12-18 | |
| US62/093,919 | 2014-12-18 | ||
| PCT/US2015/045407 WO2016028649A1 (en) | 2014-08-20 | 2015-08-14 | Modified double-stranded rna agents |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020212528A Division JP7672220B2 (ja) | 2014-08-20 | 2020-12-22 | 修飾二本鎖ｒｎａ剤 |
| JP2020212527A Division JP7370311B2 (ja) | 2014-08-20 | 2020-12-22 | 修飾二本鎖ｒｎａ剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017525705A JP2017525705A (ja) | 2017-09-07 |
| JP2017525705A5 true JP2017525705A5 (2) | 2018-09-20 |
| JP7289610B2 JP7289610B2 (ja) | 2023-06-12 |
Family
ID=53969461
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017509743A Active JP7289610B2 (ja) | 2014-08-20 | 2015-08-14 | 修飾二本鎖ｒｎａ剤 |
| JP2020212527A Active JP7370311B2 (ja) | 2014-08-20 | 2020-12-22 | 修飾二本鎖ｒｎａ剤 |
| JP2020212528A Active JP7672220B2 (ja) | 2014-08-20 | 2020-12-22 | 修飾二本鎖ｒｎａ剤 |
| JP2023178574A Active JP7654744B2 (ja) | 2014-08-20 | 2023-10-17 | 修飾二本鎖ｒｎａ剤 |
| JP2025044214A Pending JP2025111426A (ja) | 2014-08-20 | 2025-03-19 | 修飾二本鎖ｒｎａ剤 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020212527A Active JP7370311B2 (ja) | 2014-08-20 | 2020-12-22 | 修飾二本鎖ｒｎａ剤 |
| JP2020212528A Active JP7672220B2 (ja) | 2014-08-20 | 2020-12-22 | 修飾二本鎖ｒｎａ剤 |
| JP2023178574A Active JP7654744B2 (ja) | 2014-08-20 | 2023-10-17 | 修飾二本鎖ｒｎａ剤 |
| JP2025044214A Pending JP2025111426A (ja) | 2014-08-20 | 2025-03-19 | 修飾二本鎖ｒｎａ剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (12) | US10233448B2 (2) |
| EP (4) | EP3808846A1 (2) |
| JP (5) | JP7289610B2 (2) |
| KR (3) | KR102630289B1 (2) |
| CN (3) | CN118652888A (2) |
| CA (1) | CA2958758A1 (2) |
| EA (1) | EA201790420A1 (2) |
| IL (3) | IL316808A (2) |
| MX (3) | MX2017002144A (2) |
| NZ (1) | NZ730296A (2) |
| SG (3) | SG10201913791QA (2) |
| WO (1) | WO2016028649A1 (2) |
Families Citing this family (153)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA036772B1 (ru) | 2008-10-20 | 2020-12-18 | Элнилэм Фармасьютикалз, Инк. | Композиции и способы для ингибирования экспрессии транстиретина |
| ES2923573T3 (es) | 2011-06-21 | 2022-09-28 | Alnylam Pharmaceuticals Inc | Composiciones de ARNi de proteína 3 de tipo angiopoyetina (ANGPTL3) y métodos de uso de las mismas |
| EP2780454A2 (en) * | 2011-11-18 | 2014-09-24 | Alnylam Pharmaceuticals, Inc. | Modified rnai agents |
| JP6453212B2 (ja) | 2012-07-13 | 2019-01-16 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | キラル制御 |
| TW201936624A (zh) | 2013-05-22 | 2019-09-16 | 美商阿尼拉製藥公司 | 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法 |
| IL316808A (en) * | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| EP3277811B1 (en) | 2015-04-03 | 2020-12-23 | University of Massachusetts | Fully stabilized asymmetric sirna |
| EA201792263A1 (ru) | 2015-04-13 | 2018-08-31 | Элнилэм Фармасьютикалз, Инк. | КОМПОЗИЦИИ НА ОСНОВЕ iRNA ПРОТИВ АНГИОПОЭТИН-ПОДОБНОГО БЕЛКА 3 (ANGPTL3) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| CN108138182B (zh) | 2015-07-31 | 2022-08-19 | 阿尔尼拉姆医药品有限公司 | 甲状腺素运载蛋白(TTR)iRNA组合物及其治疗或预防TTR相关疾病的使用方法 |
| US10633653B2 (en) | 2015-08-14 | 2020-04-28 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
| WO2017132669A1 (en) | 2016-01-31 | 2017-08-03 | University Of Massachusetts | Branched oligonucleotides |
| MX2018009325A (es) * | 2016-02-01 | 2019-05-15 | Arrakis Therapeutics Inc | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). |
| MA45349A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques egfr et leurs utilisations |
| WO2017173297A1 (en) | 2016-04-01 | 2017-10-05 | Avidity Biosciences Llc | Beta-catenin nucleic acids and uses thereof |
| JP2019513371A (ja) | 2016-04-01 | 2019-05-30 | アビディティー バイオサイエンシーズ エルエルシー | 核酸ポリペプチド組成物とその使用 |
| WO2017173304A1 (en) | 2016-04-01 | 2017-10-05 | Avidity Biosciences Llc | Kras nucleic acids and uses thereof |
| WO2017214112A1 (en) | 2016-06-06 | 2017-12-14 | Arrowhead Pharmaceuticals, Inc. | 5'-cyclo-phosphonate modified nucleotides |
| CA3033368A1 (en) | 2016-08-12 | 2018-02-15 | University Of Massachusetts | Conjugated oligonucleotides |
| JP2019532027A (ja) * | 2016-08-17 | 2019-11-07 | ソルスティス バイオロジクス，リミティッド | ポリヌクレオチド構築物 |
| EP3535274A4 (en) * | 2016-11-07 | 2020-07-29 | Nanosur LLC | Post-transcriptionally chemically modified double stranded RNA |
| US11447519B2 (en) | 2016-11-10 | 2022-09-20 | San Diego State University Research Foundation | Compounds for fluorescence sensing of duplex formation |
| KR102645243B1 (ko) * | 2016-11-23 | 2024-03-11 | 알닐람 파마슈티칼스 인코포레이티드 | 표적외 효과가 감소된 변형 rna 작용제 |
| TW202313978A (zh) * | 2016-11-23 | 2023-04-01 | 美商阿尼拉製藥公司 | 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法 |
| US10611823B2 (en) | 2016-12-14 | 2020-04-07 | Hanssen Biotech, Inc | CD137 binding fibronectin type III domains |
| NZ754187A (en) | 2016-12-14 | 2026-02-27 | Janssen Biotech Inc | Cd8a-binding fibronectin type iii domains |
| AU2017376950B2 (en) * | 2016-12-16 | 2024-02-22 | Alnylam Pharmaceuticals, Inc. | Methods for treating or preventing TTR-associated diseases using transthyretin (TTR) iRNA compositions |
| WO2018185240A1 (en) * | 2017-04-05 | 2018-10-11 | Silence Therapeutics Gmbh | Products and compositions |
| EP3550022A1 (en) * | 2018-04-05 | 2019-10-09 | Silence Therapeutics GmbH | Products and compositions |
| WO2019193144A1 (en) * | 2018-04-05 | 2019-10-10 | Silence Therapeutics Gmbh | siRNAs WITH VINYLPHOSPHONATE AT THE 5' END OF THE ANTISENSE STRAND |
| JP7155239B2 (ja) * | 2017-04-05 | 2022-10-18 | サイレンス・セラピューティクス・ゲーエムベーハー | 産物及び組成物 |
| JP7406793B2 (ja) | 2017-06-23 | 2023-12-28 | ユニバーシティー オブ マサチューセッツ | ２テイル自己デリバリー型ｓｉＲＮＡおよび関連方法 |
| WO2019006455A1 (en) | 2017-06-30 | 2019-01-03 | Solstice Biologics, Ltd. | AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF |
| MX2020001912A (es) | 2017-09-14 | 2020-03-24 | Arrowhead Pharmaceuticals Inc | Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso. |
| KR20250046363A (ko) | 2017-09-19 | 2025-04-02 | 알닐람 파마슈티칼스 인코포레이티드 | 트랜스타이레틴(ttr) 매개 아밀로이드증을 치료하기 위한 조성물 및 방법 |
| WO2019071028A1 (en) * | 2017-10-04 | 2019-04-11 | Avidity Biosciences Llc | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF |
| IL274611B2 (en) * | 2017-11-13 | 2024-10-01 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages |
| RU2020112854A (ru) | 2017-11-30 | 2021-12-30 | Арракис Терапьютикс, Инк. | Фотозонды, связывающие нуклеиновые кислоты, и способы их применения |
| WO2019105403A1 (zh) * | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN110945130B (zh) * | 2017-12-01 | 2024-04-09 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| JP7365052B2 (ja) * | 2017-12-01 | 2023-10-19 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| CA3083968C (en) | 2017-12-01 | 2024-04-23 | Suzhou Ribo Life Science Co., Ltd. | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof |
| CN111050807B (zh) * | 2017-12-01 | 2024-05-28 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| WO2019105435A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| WO2019105437A1 (zh) * | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| JP7506601B2 (ja) | 2017-12-06 | 2024-06-26 | アビディティー バイオサイエンシーズ，インク． | 筋萎縮症と筋緊張性ジストロフィーを処置するための組成物および方法 |
| CA3086485A1 (en) * | 2017-12-21 | 2019-06-27 | Alnylam Pharmaceuticals, Inc. | Chirally-enriched double-stranded rna agents |
| WO2019127004A1 (zh) * | 2017-12-26 | 2019-07-04 | 广州市锐博生物科技有限公司 | 修饰的寡核苷酸和可用于合成修饰的寡核苷酸的化合物 |
| EP3732185B1 (en) | 2017-12-29 | 2025-02-26 | Suzhou Ribo Life Science Co., Ltd. | Conjugates and preparation and use thereof |
| CA3092089A1 (en) * | 2018-03-02 | 2019-09-06 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for treating bile duct paucity-associated conditions |
| WO2019193189A1 (en) * | 2018-04-05 | 2019-10-10 | Silence Therapeutics Gmbh | siRNAs WITH AT LEAST TWO LIGANDS AT DIFFERENT ENDS |
| WO2019217397A2 (en) * | 2018-05-07 | 2019-11-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for improving strand biased |
| WO2019217459A1 (en) | 2018-05-07 | 2019-11-14 | Alnylam Pharmaceuticals, Inc. | Extrahepatic delivery |
| WO2019222479A1 (en) * | 2018-05-16 | 2019-11-21 | Alnylam Pharmaceuticals, Inc. | Modified rna agents with reduced off-target effect |
| US11918600B2 (en) | 2018-08-21 | 2024-03-05 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof |
| JP7627042B2 (ja) * | 2018-08-23 | 2025-02-05 | ユニバーシティー オブ マサチューセッツ | Ｏ－メチルリッチ完全安定化オリゴヌクレオチド |
| WO2020069055A1 (en) * | 2018-09-28 | 2020-04-02 | Alnylam Pharmaceuticals, Inc. | Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases |
| EP3862024A4 (en) | 2018-09-30 | 2022-08-17 | Suzhou Ribo Life Science Co., Ltd. | SIRNA CONJUGATE, METHOD FOR ITS PRODUCTION AND ITS USE |
| CA3118537A1 (en) * | 2018-11-09 | 2020-05-14 | Alnylam Pharmaceuticals, Inc. | Modified double stranded oligonucleotides |
| EP3894554A1 (en) * | 2018-12-10 | 2021-10-20 | Amgen Inc. | Chemically-modified rnai constructs and uses thereof |
| PT3894549T (pt) | 2018-12-10 | 2024-10-16 | Amgen Inc | Transposase piggybac mutada |
| TW202039844A (zh) * | 2018-12-19 | 2020-11-01 | 美商阿尼拉製藥公司 | 類澱粉前驅蛋白（ＡＰＰ）ＲＮＡｉ劑組成物及其使用方法 |
| MY206794A (en) | 2018-12-20 | 2025-01-08 | Humabs Biomed Sa | Combination hbv therapy |
| CN111378658B (zh) * | 2018-12-28 | 2024-03-15 | 苏州瑞博生物技术股份有限公司 | 抑制TIMP-1基因表达的siRNA、含有该siRNA的药物组合物及其用途 |
| CN112423795A (zh) * | 2018-12-28 | 2021-02-26 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| US12496347B2 (en) | 2018-12-28 | 2025-12-16 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof |
| CN111378657B (zh) * | 2018-12-28 | 2024-03-15 | 苏州瑞博生物技术股份有限公司 | 抑制COL1A1基因表达的siRNA、含有该siRNA的药物组合物及其用途 |
| CN111378655B (zh) * | 2018-12-28 | 2024-03-19 | 苏州瑞博生物技术股份有限公司 | 抑制CTGF基因表达的siRNA、含有该siRNA的药物组合物及其用途 |
| CN111378659B (zh) * | 2018-12-29 | 2024-01-30 | 苏州瑞博生物技术股份有限公司 | 抑制stat3基因表达的核酸、含有该核酸的药物组合物及其用途 |
| CN113614232A (zh) | 2019-01-18 | 2021-11-05 | 马萨诸塞大学 | 动态药代动力学修饰锚 |
| CN113330117B (zh) * | 2019-01-18 | 2024-05-28 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| US20200385737A1 (en) * | 2019-03-29 | 2020-12-10 | University Of Massachusetts | OLIGONUCLEOTIDE-BASED MODULATION OF C9orf72 |
| CN114072501A (zh) | 2019-05-06 | 2022-02-18 | 马萨诸塞大学 | 抗c9orf72寡核苷酸及相关方法 |
| SG11202112240VA (en) * | 2019-05-13 | 2021-12-30 | Vir Biotechnology Inc | Compositions and methods for treating hepatitis b virus (hbv) infection |
| JP2022532652A (ja) * | 2019-05-17 | 2022-07-15 | アルニラム ファーマスーティカルズ インコーポレイテッド | オリゴヌクレオチドの経口送達 |
| WO2020233680A1 (zh) | 2019-05-22 | 2020-11-26 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| AU2020280438B2 (en) * | 2019-05-22 | 2025-03-06 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| JP7610268B2 (ja) | 2019-05-22 | 2025-01-08 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
| CN111973619B (zh) * | 2019-05-23 | 2024-01-30 | 苏州瑞博生物技术股份有限公司 | 核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途 |
| CA3140233A1 (en) * | 2019-05-24 | 2020-12-03 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate, preparation method and use |
| US20220315929A1 (en) * | 2019-05-24 | 2022-10-06 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate, preparation method therefor and use thereof |
| EP3978609A4 (en) | 2019-05-24 | 2024-02-07 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| TW202111124A (zh) * | 2019-05-30 | 2021-03-16 | 美商安進公司 | 用於抑制ｓｃａｐ表現之ｒｎａｉ構建體及其使用方法 |
| CN112007040B (zh) * | 2019-05-31 | 2024-01-30 | 苏州瑞博生物技术股份有限公司 | 用于治疗乙型病毒性肝炎的联合用药物 |
| JP7592034B2 (ja) | 2019-06-06 | 2024-11-29 | アビディティー バイオサイエンシーズ，インク． | 核酸ポリペプチド組成物およびその使用 |
| KR20220019259A (ko) | 2019-06-06 | 2022-02-16 | 어비디티 바이오사이언시스 인크. | Una 아미다이트 및 이의 용도 |
| CA3138627A1 (en) * | 2019-06-21 | 2020-12-24 | Alexander V. KEL'IN | Structurally defined sirna-dual variable domain immunoglobulin conjugates |
| MX2022001710A (es) | 2019-08-09 | 2022-05-10 | Univ Massachusetts | Oligonucleótidos modificados químicamente dirigidos a los snp. |
| EP4013767A4 (en) | 2019-08-15 | 2023-10-25 | Ionis Pharmaceuticals, Inc. | Linkage modified oligomeric compounds and uses thereof |
| US12365894B2 (en) | 2019-09-16 | 2025-07-22 | University Of Massachusetts | Branched lipid conjugates of siRNA for specific tissue delivery |
| WO2021076543A1 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Epcam binding fibronectin type iii domains |
| CN114786682B (zh) | 2019-10-14 | 2024-07-16 | Aro生物疗法公司 | 结合cd71的纤维粘连蛋白iii型结构域 |
| WO2021076574A2 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Fn3 domain-sirna conjugates and uses thereof |
| CA3160329A1 (en) * | 2019-11-06 | 2021-05-14 | Alnylam Pharmaceuticals, Inc. | Extrahepatic delivery |
| EP4055165A1 (en) * | 2019-11-06 | 2022-09-14 | Alnylam Pharmaceuticals, Inc. | Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases |
| CN112876534B (zh) * | 2019-11-29 | 2024-02-09 | 苏州瑞博生物技术股份有限公司 | 肝靶向化合物及缀合物 |
| KR20220152270A (ko) * | 2020-03-06 | 2022-11-15 | 알닐람 파마슈티칼스 인코포레이티드 | 트랜스티레틴 (ttr)의 발현을 억제하기 위한 조성물 및 방법 |
| US11555190B2 (en) | 2020-03-19 | 2023-01-17 | Avidity Biosciences, Inc. | Compositions and methods of treating Facioscapulohumeral muscular dystrophy |
| AU2021241682B2 (en) | 2020-03-27 | 2026-02-12 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle dystrophy |
| AU2021246024A1 (en) * | 2020-03-30 | 2022-10-27 | Alnylam Pharmaceuticals, Inc. | Microtubule associated protein Tau (MAPT) iRNA agent compositions and methods of use thereof |
| WO2021204216A1 (zh) * | 2020-04-08 | 2021-10-14 | 北京瑞博开拓医药科技有限公司 | 核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途 |
| WO2021242883A1 (en) | 2020-05-26 | 2021-12-02 | University Of Massachusetts | Synthetic oligonucleotides having regions of block and cluster modifications |
| US20230340485A1 (en) * | 2020-06-16 | 2023-10-26 | Alnylam Pharmaceuticals, Inc. | ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
| US20230257745A1 (en) | 2020-07-10 | 2023-08-17 | Alnylam Pharmaceuticals, Inc. | Circular siRNAs |
| EP4189088A4 (en) * | 2020-07-30 | 2025-06-04 | Adarx Pharmaceuticals, Inc. | Adar dependent editing compositions and methods of use thereof |
| US12329828B2 (en) | 2020-09-16 | 2025-06-17 | San Diego State University (Sdsu) Foundation | Pyrimidine nucleoside compounds for fluorescence imaging and spectroscopy |
| CN115516092B (zh) * | 2020-09-30 | 2025-05-16 | 亿腾医药（苏州）有限公司 | 血管生成素样3(ANGPTL3)的siRNA及其用途 |
| CR20230308A (es) | 2020-12-11 | 2023-09-08 | Civi Biopharma Inc | Entrega oral de conjugados antisentido que tienen por blanco a pcsk9 |
| CN114685585B (zh) * | 2020-12-31 | 2024-06-04 | 苏州瑞博生物技术股份有限公司 | 核苷酸序列、双链寡核苷酸、药物组合物与缀合物及制备方法和用途 |
| EP4277636A4 (en) * | 2021-01-15 | 2025-11-26 | Alnylam Pharmaceuticals Inc | MODIFIED OLIGONUCLEOTIDES |
| MX2023008469A (es) * | 2021-01-22 | 2023-11-22 | Alnylam Pharmaceuticals Inc | Oligonucleotidos de doble hebra modificados. |
| WO2022174000A2 (en) | 2021-02-12 | 2022-08-18 | Alnylam Pharmaceuticals, Inc. | Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases |
| IL305442A (en) | 2021-03-04 | 2023-10-01 | Alnylam Pharmaceuticals Inc | Angiopoietin-like 3 (ANGPTL3) IRNA compositions and methods of using them |
| WO2022189861A1 (en) | 2021-03-08 | 2022-09-15 | Tollys | Carbohydrate conjugates of tlr3 ligands and uses thereof |
| WO2022212231A2 (en) | 2021-03-29 | 2022-10-06 | Alnylam Pharmaceuticals, Inc. | Huntingtin (htt) irna agent compositions and methods of use thereof |
| CA3214552A1 (en) | 2021-04-14 | 2022-10-20 | Russell C. Addis | Cd71 binding fibronectin type iii domains |
| BR112023021318A2 (pt) | 2021-04-14 | 2023-12-19 | Aro Biotherapeutics Company | Conjugados de domínio fn3-sirna e usos dos mesmos |
| AU2022299169A1 (en) | 2021-06-23 | 2024-02-08 | Beth Israel Deaconess Medical Center, Inc. | Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders |
| WO2023283403A2 (en) | 2021-07-09 | 2023-01-12 | Alnylam Pharmaceuticals, Inc. | Bis-rnai compounds for cns delivery |
| TW202421169A (zh) | 2021-07-21 | 2024-06-01 | 美商艾拉倫製藥股份有限公司 | 代謝疾患相關的標靶基因ｉＲＮＡ組成物及其使用方法 |
| CA3227852A1 (en) | 2021-08-03 | 2023-02-09 | Alnylam Pharmaceuticals, Inc. | Transthyretin (ttr) irna compositions and methods of use thereof |
| MX2024003266A (es) | 2021-09-16 | 2024-04-03 | Avidity Biosciences Inc | Composiciones y metodos de tratamiento de la distrofia muscular facioescapulohumeral. |
| KR20240067943A (ko) | 2021-09-24 | 2024-05-17 | 알닐람 파마슈티칼스 인코포레이티드 | 미소관 연관 단백질 타우(MAPT) iRNA 제제 조성물 및 이의 사용 방법 |
| MX2024004437A (es) | 2021-10-15 | 2024-07-01 | Alnylam Pharmaceuticals Inc | Composiciones de inhibidor de la angiotensina-receptor neprilisina (arni) de administracion extrahepatica y metodos de uso de las mismas. |
| US20250223588A1 (en) * | 2021-10-19 | 2025-07-10 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides with 2'-deoxy-2'-f-2'-c-methyl nucleotides |
| IL312811A (en) | 2021-11-16 | 2024-07-01 | Shanghai Argo Biopharmaceutical Co Ltd | Composition and method for inhibiting angiotensinogen (agt) protein expression |
| WO2023109932A1 (zh) * | 2021-12-16 | 2023-06-22 | 上海拓界生物医药科技有限公司 | 一种dsRNA、其制备方法及应用 |
| CN119320418A (zh) * | 2022-01-05 | 2025-01-17 | 大睿生物医药科技(上海)有限公司 | 具有核苷酸类似物的双链rna |
| JPWO2023176863A1 (2) | 2022-03-16 | 2023-09-21 | ||
| KR20240161967A (ko) | 2022-03-16 | 2024-11-13 | 다이이찌 산쿄 가부시키가이샤 | 트랜스페린 수용체 2 의 발현을 억제하는 siRNA |
| EP4493570A2 (en) | 2022-03-16 | 2025-01-22 | Empirico Inc. | Galnac compositions for improving sirna bioavailability |
| KR20240163743A (ko) | 2022-03-28 | 2024-11-19 | 엠피리코 인크. | 변형된 올리고뉴클레오티드 |
| AU2023356356A1 (en) * | 2022-10-07 | 2025-04-10 | Alnylam Pharmaceuticals, Inc. | Plasminogen (plg) irna compositions and methods of use thereof |
| AU2023408479A1 (en) | 2022-12-19 | 2025-05-01 | Arnatar Therapeutics, Inc | Advanced rna targeting (arnatar) |
| JP2026503499A (ja) | 2023-01-20 | 2026-01-29 | 石薬集団中奇制薬技術（石家庄）有限公司 | 修飾されたヌクレオシド単量体及び二本鎖リボ核酸 |
| WO2024175586A2 (en) | 2023-02-21 | 2024-08-29 | Vib Vzw | Inhibitors of synaptogyrin-3 expression |
| JP2026507051A (ja) | 2023-02-21 | 2026-02-27 | ブイアイビー ブイゼットダブリュ | シナプトギリン－３発現を調節するためのオリゴヌクレオチド |
| CN121194983A (zh) | 2023-04-06 | 2025-12-23 | 上海舶望制药有限公司 | 5'-膦酸酯修饰的核苷类似物及其制备的寡核苷酸 |
| WO2024229377A1 (en) * | 2023-05-03 | 2024-11-07 | Ionis Pharmaceuticals, Inc. | Sugar modified oligonucleotides and uses thereof |
| TW202508607A (zh) * | 2023-05-19 | 2025-03-01 | 大陸商北京炫景瑞醫藥科技有限公司 | 雙股寡核苷酸及其共軛物和用途 |
| EP4562158A1 (en) | 2023-06-13 | 2025-06-04 | Arnatar Therapeutics, Inc | Advanced rna targeting (arnatar) for angiotensinogen |
| WO2024263883A2 (en) * | 2023-06-22 | 2024-12-26 | The University Of North Carolina At Chapel Hill | 5' antisense dna modifications to enhance rna interference activity |
| CN121794380A (zh) | 2023-06-27 | 2026-04-03 | 艾维迪提生物科学公司 | 使用prkag2靶向性抗体-寡核苷酸缀合物的组合物和方法 |
| WO2025007063A1 (en) | 2023-06-30 | 2025-01-02 | Avidity Biosciences, Inc. | Compositions and methods of using pln-targeting antibody-oligonucleotide conjugates |
| CN118063533B (zh) * | 2023-09-18 | 2024-08-27 | 广州必贝特医药股份有限公司 | 修饰的核苷酸化合物、其寡聚核苷酸及其应用 |
| WO2025064660A2 (en) | 2023-09-21 | 2025-03-27 | Alnylam Pharmaceuticals, Inc. | Activin a receptor type 1c (acvr1c) irna compositions and methods of use thereof |
| CN117534717A (zh) * | 2024-01-09 | 2024-02-09 | 凯莱英生命科学技术(天津)有限公司 | 5′-(e)-乙烯基磷酸酯的合成方法 |
| EP4671372A3 (en) | 2024-01-29 | 2026-03-11 | Arnatar Therapeutics, Inc | Translation enhancing nucleic acid compounds: aso coupled translation - upregulation 1 (act-up1) and uses thereof |
| WO2025165891A1 (en) | 2024-01-29 | 2025-08-07 | Arnatar Therapeutics, Inc | Translation enhancing nucleic acid compounds: aso coupled translation - upregulation 1 (act-up1) and uses thereof |
| TW202602463A (zh) | 2024-03-22 | 2026-01-16 | 日商武田藥品工業股份有限公司 | 用於抑制細胞色素ｐ４５０家族７次家族ａ成員１（ｃｙｐ７ａ１）表現之組成物及方法 |
| WO2026041784A1 (en) | 2024-08-23 | 2026-02-26 | Vib Vzw | Oligonucleotides for modulating synaptogyrin-3 expression |
| WO2026054553A1 (ko) * | 2024-09-06 | 2026-03-12 | 올릭스 주식회사 | 선천성 면역 반응 기반 항암 요법을 위한 이중 가닥 rna 및 이의 용도 |
| WO2026052079A1 (zh) * | 2024-09-07 | 2026-03-12 | 苏州瑞博生物技术股份有限公司 | 寡核苷酸、寡核苷酸缀合物及组合物和用途 |
| WO2026052078A1 (zh) * | 2024-09-07 | 2026-03-12 | 苏州瑞博生物技术股份有限公司 | 寡核苷酸、寡核苷酸缀合物及组合物和用途 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1861608A (en) | 1929-12-21 | 1932-06-07 | Emerson Electric Mfg Co | Fan and means for directing the air current therethrough |
| US1861108A (en) | 1930-01-24 | 1932-05-31 | Eugene O Brace | Integral clutch and transmission control |
| US3974808A (en) | 1975-07-02 | 1976-08-17 | Ford Motor Company | Air intake duct assembly |
| US4708708A (en) | 1982-12-06 | 1987-11-24 | International Paper Company | Method and apparatus for skiving and hemming |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| FR2645866B1 (fr) | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | Nouvelles lipopolyamines, leur preparation et leur emploi |
| NL8901881A (nl) | 1989-07-20 | 1991-02-18 | Rockwool Grodan Bv | Drainagekoppelelement. |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
| JPH07508410A (ja) | 1992-06-18 | 1995-09-21 | ジェンファーム インターナショナル インコーポレイテッド | 酵母人工染色体を有するトランスジェニック非ヒト動物の製造方法 |
| JPH11508231A (ja) | 1995-05-26 | 1999-07-21 | ソマティックス セラピー コーポレイション | 安定な脂質／核酸複合体を含む送達ビヒクル |
| US6034135A (en) | 1997-03-06 | 2000-03-07 | Promega Biosciences, Inc. | Dimeric cationic lipids |
| US8273866B2 (en) * | 2002-02-20 | 2012-09-25 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA) |
| WO2005078097A2 (en) | 2004-02-10 | 2005-08-25 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING MULTIFUNCTIONAL SHORT INTERFERING NUCLEIC ACID (Multifunctional siNA) |
| US7683036B2 (en) * | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
| EP2399924B1 (en) | 2004-05-27 | 2015-01-28 | Alnylam Pharmaceuticals, Inc. | Nuclease resistant double-stranded ribonucleic acid |
| CH698304B1 (de) | 2005-10-10 | 2009-07-15 | Fatzer Ag | Drahtseilanker, insbesondere für Steinschlag- oder Lawinenschutzverbauungen. |
| US8101741B2 (en) * | 2005-11-02 | 2012-01-24 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
| EP1989307B1 (en) | 2006-02-08 | 2012-08-08 | Quark Pharmaceuticals, Inc. | NOVEL TANDEM siRNAS |
| EP2021008B1 (en) | 2006-04-07 | 2015-12-02 | Idera Pharmaceuticals, Inc. | Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8 |
| WO2008100447A2 (en) | 2007-02-09 | 2008-08-21 | Gilead Sciences, Inc. | Nucleoside analogs for antiviral treatment |
| CA2692161C (en) | 2007-07-09 | 2015-09-29 | Idera Pharmaceuticals, Inc. | Stabilized immune modulatory rna (simra) compounds |
| US10131904B2 (en) * | 2008-02-11 | 2018-11-20 | Rxi Pharmaceuticals Corporation | Modified RNAi polynucleotides and uses thereof |
| US20110223665A1 (en) | 2008-07-25 | 2011-09-15 | Alnylam Pharmaceuticals, Inc. | ENHANCEMENT OF siRNA SILENCING ACTIVITY USING UNIVERSAL BASES OR MISMATCHES IN THE SENSE STRAND |
| US20100183704A1 (en) * | 2008-09-25 | 2010-07-22 | Novartis Ag | dsRNA FOR TREATING VIRAL INFECTION |
| ES2804764T3 (es) | 2009-06-01 | 2021-02-09 | Halo Bio Rnai Therapeutics Inc | Polinucleótidos para la interferencia de ARN multivalente, composiciones y métodos de uso de los mismos |
| DK2470656T3 (da) | 2009-08-27 | 2015-06-22 | Idera Pharmaceuticals Inc | Sammensætning til hæmning af genekspression og anvendelser heraf |
| WO2011109427A2 (en) * | 2010-03-01 | 2011-09-09 | Alnylam Pharmaceuticals, Inc. | Improving the biological activity of sirna through modulation of its thermodynamic profile |
| US10913767B2 (en) | 2010-04-22 | 2021-02-09 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising acyclic and abasic nucleosides and analogs |
| WO2011133871A2 (en) * | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
| KR101869570B1 (ko) * | 2010-04-28 | 2018-06-20 | 아이오니스 파마수티컬즈, 인코포레이티드 | 변형된 뉴클레오사이드 및 그로부터 제조된 올리고머 화합물 |
| KR102365961B1 (ko) | 2011-03-29 | 2022-02-23 | 알닐람 파마슈티칼스 인코포레이티드 | Tmprss6 유전자의 발현을 억제하기 위한 조성물 및 방법 |
| WO2012177949A2 (en) | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of expression of protein c (proc) genes |
| CN103649103A (zh) | 2011-06-21 | 2014-03-19 | 阿尔尼拉姆医药品有限公司 | 用于抑制载脂蛋白c-iii(apoc3)基因表达的组合物与方法 |
| ES2923573T3 (es) | 2011-06-21 | 2022-09-28 | Alnylam Pharmaceuticals Inc | Composiciones de ARNi de proteína 3 de tipo angiopoyetina (ANGPTL3) y métodos de uso de las mismas |
| EP2723861A4 (en) | 2011-06-21 | 2014-12-10 | Alnylam Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR INHIBITING HEPCIDINE ANTIMICROBIAL PEPTIDE (HAMP) OR THE ASSOCIATED GENE EXPRESSION |
| EP3366312A1 (en) | 2011-06-23 | 2018-08-29 | Alnylam Pharmaceuticals, Inc. | Serpina 1 sirnas: compositions of matter and methods of treatment |
| EP2780454A2 (en) * | 2011-11-18 | 2014-09-24 | Alnylam Pharmaceuticals, Inc. | Modified rnai agents |
| HUE048622T2 (hu) * | 2011-11-18 | 2020-08-28 | Alnylam Pharmaceuticals Inc | RNSi szerek, készítmények és alkalmazási eljárások transztiretin (TTR) asszociált betegségek kezelésére |
| US9133461B2 (en) * | 2012-04-10 | 2015-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the ALAS1 gene |
| US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
| AU2013299717B2 (en) * | 2012-08-06 | 2018-06-28 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugated RNA agents and process for their preparation |
| DK2895608T3 (en) * | 2012-09-12 | 2019-01-21 | Quark Pharmaceuticals Inc | DOUBLE-STRENGTHED OIGONUCLEOTIDE MOLECULES FOR P53 AND PROCEDURES FOR USING IT |
| US9932578B2 (en) * | 2012-09-12 | 2018-04-03 | Quark Pharmaceuticals, Inc. | Double-stranded oligonucleotide molecules to P53 and methods of use thereof |
| US10125369B2 (en) * | 2012-12-05 | 2018-11-13 | Alnylam Pharmaceuticals, Inc. | PCSK9 iRNA compositions and methods of use thereof |
| CA3216595A1 (en) | 2013-03-14 | 2014-10-02 | Kevin Fitzgerald | Complement component c5 irna compositions and methods of use thereof |
| KR102486617B1 (ko) | 2013-05-22 | 2023-01-12 | 알닐람 파마슈티칼스 인코포레이티드 | Ｔｍｐｒｓｓ6 조성물 및 이의 사용 방법 |
| TW201936624A (zh) | 2013-05-22 | 2019-09-16 | 美商阿尼拉製藥公司 | 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法 |
| TW201610151A (zh) | 2013-09-23 | 2016-03-16 | 阿尼拉製藥公司 | 治療或預防與甲狀腺素運載蛋白相關疾病之方法 |
| US10077444B2 (en) | 2013-10-02 | 2018-09-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the LECT2 gene |
| TWI768330B (zh) | 2013-10-04 | 2022-06-21 | 美國西奈山伊坎醫學院 | 抑制alas1基因表現的組合物及方法 |
| EP3065783A4 (en) * | 2013-11-06 | 2017-06-21 | Merck Sharp & Dohme Corp. | Dual molecular delivery of oligonucleotides and peptide containing conjugates |
| SG10201804960RA (en) | 2013-12-12 | 2018-07-30 | Alnylam Pharmaceuticals Inc | Complement component irna compositions and methods of use thereof |
| AU2015217301A1 (en) | 2014-02-11 | 2016-08-25 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (KHK) iRNA compositions and methods of use thereof |
| CA3215908A1 (en) | 2014-05-22 | 2015-11-26 | Alnylam Pharmaceuticals, Inc. | Angiotensinogen (agt) irna compositions and methods of use thereof |
| IL316808A (en) | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| KR102054401B1 (ko) | 2018-03-26 | 2019-12-10 | 주식회사 엔지켐생명과학 | 1,2-디아실글리세롤 화합물, 그 제조방법 및 이를 유효성분으로 함유하는 면역조절제 |
| KR102318555B1 (ko) | 2020-03-19 | 2021-10-29 | 한국과학기술연구원 | 광소자용 역나노콘과 그 제조방법 |
-
2015
- 2015-08-13 IL IL316808A patent/IL316808A/en unknown
- 2015-08-14 NZ NZ730296A patent/NZ730296A/en unknown
- 2015-08-14 EP EP20203314.8A patent/EP3808846A1/en active Pending
- 2015-08-14 KR KR1020237002505A patent/KR102630289B1/ko active Active
- 2015-08-14 WO PCT/US2015/045407 patent/WO2016028649A1/en not_active Ceased
- 2015-08-14 EP EP15754100.4A patent/EP3186377A1/en not_active Withdrawn
- 2015-08-14 EP EP20203754.5A patent/EP3812462A1/en active Pending
- 2015-08-14 CN CN202410668845.1A patent/CN118652888A/zh active Pending
- 2015-08-14 KR KR1020177007371A patent/KR102494171B1/ko active Active
- 2015-08-14 US US15/504,855 patent/US10233448B2/en active Active
- 2015-08-14 SG SG10201913791QA patent/SG10201913791QA/en unknown
- 2015-08-14 CA CA2958758A patent/CA2958758A1/en active Pending
- 2015-08-14 MX MX2017002144A patent/MX2017002144A/es unknown
- 2015-08-14 SG SG11201701166UA patent/SG11201701166UA/en unknown
- 2015-08-14 IL IL280941A patent/IL280941B2/en unknown
- 2015-08-14 CN CN201580056832.8A patent/CN107075516A/zh active Pending
- 2015-08-14 JP JP2017509743A patent/JP7289610B2/ja active Active
- 2015-08-14 EA EA201790420A patent/EA201790420A1/ru unknown
- 2015-08-14 SG SG10201903290YA patent/SG10201903290YA/en unknown
- 2015-08-14 CN CN202111550874.0A patent/CN114181942B/zh active Active
- 2015-08-14 KR KR1020247001789A patent/KR20240010762A/ko active Pending
- 2015-08-14 EP EP25172177.5A patent/EP4585686A3/en active Pending
-
2017
- 2017-02-05 IL IL250448A patent/IL250448B/en active IP Right Grant
- 2017-02-16 MX MX2024005653A patent/MX2024005653A/es unknown
- 2017-02-16 MX MX2024005652A patent/MX2024005652A/es unknown
-
2019
- 2019-02-11 US US16/272,721 patent/US10612024B2/en active Active
- 2019-04-15 US US16/384,644 patent/US10612027B2/en active Active
- 2019-11-25 US US16/693,683 patent/US11401517B2/en active Active
-
2020
- 2020-12-22 JP JP2020212527A patent/JP7370311B2/ja active Active
- 2020-12-22 JP JP2020212528A patent/JP7672220B2/ja active Active
-
2021
- 2021-09-20 US US17/479,617 patent/US20220002727A1/en not_active Abandoned
- 2021-11-10 US US17/523,240 patent/US11427822B2/en active Active
-
2022
- 2022-06-23 US US17/847,550 patent/US11549109B2/en active Active
- 2022-09-09 US US17/941,436 patent/US12378553B2/en active Active
- 2022-12-22 US US18/145,238 patent/US12168767B2/en active Active
-
2023
- 2023-10-17 JP JP2023178574A patent/JP7654744B2/ja active Active
-
2024
- 2024-08-23 US US18/814,067 patent/US12385043B2/en active Active
- 2024-10-08 US US18/909,918 patent/US12385044B2/en active Active
-
2025
- 2025-03-13 US US19/079,175 patent/US20260098263A1/en active Pending
- 2025-03-19 JP JP2025044214A patent/JP2025111426A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017525705A5 (2) | ||
| IL316808A (en) | Modified double-stranded RNA materials and their uses | |
| JP2017532038A5 (2) | ||
| JP2018529732A5 (2) | ||
| JP2019503394A5 (2) | ||
| ES2924806T3 (es) | Análogos de 4'-fosfato y oligonucleótidos que comprenden el mismo | |
| JP2014054250A5 (2) | ||
| HRP20220908T1 (hr) | MODIFICIRANA RNAi SREDSTVA | |
| JP2021533804A5 (2) | ||
| JP2020500929A5 (2) | ||
| JP2018516091A5 (2) | ||
| JP2019214587A5 (2) | ||
| HRP20210612T1 (hr) | Postupci i pripravci za specifičnu inhibiciju glikolat oksidaze (hao1) pomoću dvolančane rnk | |
| TW201922264A (zh) | 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法 | |
| JP2016522674A5 (2) | ||
| JP2018536689A5 (2) | ||
| JP2017505623A5 (2) | ||
| JP2018531037A5 (2) | ||
| JP2013541334A5 (2) | ||
| HRP20160336T1 (hr) | Protusmjerna nukleinska kiselina | |
| HRP20211971T1 (hr) | Pripravci i postupci za inhibiciju ekspresije gena hao1 (hidroksikiselina oksidaza 1 (glikolat oksidaza)) | |
| JP2016518841A (ja) | 細胞取り込みの向上のための化合物および方法 | |
| JP2016520310A5 (2) | ||
| JP2020529197A5 (2) | ||
| RU2020115761A (ru) | МОЛЕКУЛЫ НУКЛЕИНОВЫХ КИСЛОТ ДЛЯ УМЕНЬШЕНИЯ УРОВНЯ мРНК PAPD5 ИЛИ PAPD7 ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИОННОГО ГЕПАТИТА В |